A clinical trial of levamisole in primary biliary cirrhosis.
A small pilot study of levamisole in primary biliary cirrhosis failed to demonstrate any improvement in liver function and immunological abnormalities even in 'early' cases. This may be due to the fact that the defect in the immune system lies in its afferent arm. At present, levamisole, which is potentially toxic, cannot be recommended in conventional doses for the treatment of this disease.
D002986:Clinical Trials as Topic; D006801:Humans; D007978:Levamisole / Q000627:therapeutic use*; D008105:Liver Cirrhosis, Biliary / Q000188:drug therapy* / Q000276:immunology; D010865:Pilot Projects
D007978:Levamisole